“Phase 1 Study of Fianlimab, a Human Lymphocyte Activation Gene-3 Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma: Expansion Cohort Analysis”. SKIN The Journal of Cutaneous Medicine 7, no. 2 (March 13, 2023): s179. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/1997.